Oct 25, 2023 · To determine your eligibility for Elahere, your doctor must test your cancer for FRα expression. FOR1, the commercial version of this test, is readily available. If your FOR1 test is positive, it means that you have high levels of FRα and may benefit from Elahere.

Elahere is the first and only fully approved treatment for ovarian cancer that has come back and does not respond to chemotherapy. Clinical studies suggest that Elahere increases survival rates by 33% and delays disease spread by 35% compared to standard treatments.

Oct 25, 2023 · A new breakthrough drug, Elahere (generic name: mirvetuximab soravtansine-gynx) offers hope to certain patients with ovarian cancers that have become resistant to conventional treatments and whose tumors express a high level of a protein on their surface, namely folate receptor-α (FRα).

May 11, 2024 · After 4+ years of successful treatment with Carboplatin for metastatic ovarian cancer the carbo has stopped working. This week I will start a brand new drug called Elahere that was just given full approval in the U.S. on March 22. I am excited but also scared since one of the serious potential side effects is impaired vision!

May 6, 2023 · I am currently in an adc (antibody drug conjugate -- like Elahere) clinical trial for dosing using the FRa receptor and the payload exatecan. If this does not prove effective, I will switch to Elahere, as I tested 97% for FRa receptor.

Jan 24, 2024 · My wife started on Elahere last week in December of 23. CA125 was around 1,000 right before starting. At 2nd dosing, it fell below 500. At 3rd dosing, it dropped below 250. We …

Jul 26, 2024 · I started Elahere/Carbo in January 2024 and I am now ending Cycle 7 with a 20% of ovarian cancer stage 4 growth since starting it and have slight growth in my CA 125.

Your eligibility for Elahere depends on having exceptionally high levels (exceeding 75%) of the FRα protein. While research suggests that roughly 80% of both new and recurring ovarian cancers might have this protein, only around 35-40% of cancers resistant to platinum treatment exhibit such high levels.

Nov 22, 2022 · Up to one-third of the patients receiving Elahere may experience a clinically meaningful reduction in the amount of ovarian cancer in their bodies. This effect may last for 6-7 months on average. Common side effects associated with Elahere include fatigue, nausea, diarrhea, and visual disturbances.

Mar 15, 2025 · ELAHERE® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients